| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 548333500 | Having -C(=X)-, wherein X is chalcogen, bonded directly to the diazole ring | 21 |
| 20080200690 | Preparation of 2-Substituted 4-Chloro-5-Formylimidazole and 5-Formylimidazole - The invention relates to a preparation process for 2-substituted 5-formylimidazoles, wherein the intermediate high-pressurized synthesis of an 2-substituted 4-hydroxymethylimidazole as known in the art is conveniently avoided, and wherein much higher yields are obtained. Instead, it is proposed to prepare such 2-substituted 5-formylimidazoles via a one-pot synthesis involving 2-substituted 4-chloro-5-formylimidazole, thereby employing an additional hydrodehalogenation step. Moreover, it is found that the yield and purity of 2-substituted 4-chloro-5-formylimidazole itself can be significantly improved using a triflate catalyst in the preparation process. | 08-21-2008 |
| 20090306399 | METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND - Disclosed is a commercially suitable method for producing a 1-substituted-5-acylimidazole compound. A 1-substituted-5-acylimidazole compound is produced with a high position selectivity by reacting an N-substituted amidine compound or a salt thereof with a ketone compound in the presence of a base. | 12-10-2009 |
| 20100105921 | N-HETEROCYCLIC CARBENE (NHC) CATALYZED SYNTHESIS OF HYDROXAMIC ACIDS - A process for preparing hydroxamic acids is provided. The process comprises reacting an aldehyde with a nitroso compound in the presence of a N-heterocyclic carbene (NHC) catalyst. | 04-29-2010 |
| 20110098482 | METHODS OF PREPARING 1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE - Methods of preparing 1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone and derivatives thereof are disclosed. | 04-28-2011 |
| 20130102789 | HAFNIUM COMPLEXES OF HETEROCYCLIC ORGANIC LIGANDS - Hafnium complexes of heterocyclic organic ligands having improved solubility in aliphatic hydrocarbon solvents and their use as components of olefin polymerization catalysts as well as novel syntheses of component parts thereof are disclosed. | 04-25-2013 |
| 20130109865 | METHODS OF PREPARING 1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE | 05-02-2013 |
| 20160376232 | KINASE INHIBITORS - There are provided compounds of formula IIb, | 12-29-2016 |
| 548334100 | The -C(=X)- is bonded directly to ring nitrogen of the diazole ring | 4 |
| 20080275251 | Novel Intermediates and Their Use - The invention is directed to novel acyloxy imidazole intermediates useful for making certain C-14 oxycarbonyl carbamate pleuromutilin derivatives. The invention is further directed to a process for making such acyloxy imidazole intermediates and to a process for making C-14 oxycarbonyl carbamate pleuromutilin derivatives using such acyloxy imidazole intermediates. | 11-06-2008 |
| 20100041898 | Electronically Tuned Ligands For Asymmetric Hydrogenation - Disclosed is a new class of chiral bidentate ligands capable of performing asymmetric hydrogenation. Also disclosed are processes of performing asymmetric hydrogenation the chiral bidentate ligands. | 02-18-2010 |
| 20110201823 | SALT AND PROCESS FOR PRODUCING ACID GENERATOR - A salt represented by the formula (I0): | 08-18-2011 |
| 20150299135 | CRYSTAL CONTAINING UNSATURATED CARBOXYLIC ACID AMIDE COMPOUND AND METHOD FOR PRODUCING SAME - Provided is a high-purity crystal of an unsaturated carboxylic acid amide compound which is useful as or for fine chemicals such as pharmaceuticals, agricultural chemicals, polymeric materials, functional materials, and intermediates of them. | 10-22-2015 |
| 548334500 | The -C(=X)- is part of a -C(=X)X- group, wherein the X`s are the same or diverse chalcogens (e.g., imidazole- 4,5-dicarboxylic acid, etc.) | 5 |
| 20080207916 | Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives - The invention relates to radioactively labeled derivatives of (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid esters, uses, and methods for preparing these compounds. | 08-28-2008 |
| 20090156830 | Substituted Imidazoline Compounds - The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-κB. | 06-18-2009 |
| 20090306400 | CONVERGENT PROCESS FOR THE SYNTHESIS OF TAXANE DERIVATIVES. - The present invention is broadly directed to novel compounds useful for the synthesis of biologically active compounds, including taxane derivatives, and convergent processes for the preparation of these taxane derivatives and their intermediates. | 12-10-2009 |
| 20120095237 | Process for the Preparation of 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylates - The present invention discloses a process for obtaining 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate (formula I) by the reaction of 4,4-dimethyl-2-propyl-4,6-dihydrofuro[3,4-d]imidazole (formula II), or its hydrolysis product, or its ring-opening product, with alcohol under appropriate catalytic conditions. Furthermore, the present invention also provides a process for obtaining high purity 4,4-dimethyl-2-propyl-4,6-dihydrofuro[3,4-d]imidazole (formula II), therefore purified compound of formula I can be produced. Producing of olmesartan medoxomil at high purity is assured by said processes. R in formula I is selected from C | 04-19-2012 |
| 20130338372 | Substituted Imidazoline Compounds - The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-κB. | 12-19-2013 |
| 20080207916 | Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives - The invention relates to radioactively labeled derivatives of (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid esters, uses, and methods for preparing these compounds. | 08-28-2008 |
| 20090156830 | Substituted Imidazoline Compounds - The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-κB. | 06-18-2009 |
| 20090306400 | CONVERGENT PROCESS FOR THE SYNTHESIS OF TAXANE DERIVATIVES. - The present invention is broadly directed to novel compounds useful for the synthesis of biologically active compounds, including taxane derivatives, and convergent processes for the preparation of these taxane derivatives and their intermediates. | 12-10-2009 |
| 20120095237 | Process for the Preparation of 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylates - The present invention discloses a process for obtaining 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate (formula I) by the reaction of 4,4-dimethyl-2-propyl-4,6-dihydrofuro[3,4-d]imidazole (formula II), or its hydrolysis product, or its ring-opening product, with alcohol under appropriate catalytic conditions. Furthermore, the present invention also provides a process for obtaining high purity 4,4-dimethyl-2-propyl-4,6-dihydrofuro[3,4-d]imidazole (formula II), therefore purified compound of formula I can be produced. Producing of olmesartan medoxomil at high purity is assured by said processes. R in formula I is selected from C | 04-19-2012 |
| 20130338372 | Substituted Imidazoline Compounds - The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-κB. | 12-19-2013 |
| 548334500 | The -C(=X)- is part of a -C(=X)X- group, wherein the Xs are the same or diverse chalcogens (e.g., imidazole- 4,5-dicarboxylic acid, etc.) | 5 |
| 20080207916 | Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives - The invention relates to radioactively labeled derivatives of (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid esters, uses, and methods for preparing these compounds. | 08-28-2008 |
| 20090156830 | Substituted Imidazoline Compounds - The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-κB. | 06-18-2009 |
| 20090306400 | CONVERGENT PROCESS FOR THE SYNTHESIS OF TAXANE DERIVATIVES. - The present invention is broadly directed to novel compounds useful for the synthesis of biologically active compounds, including taxane derivatives, and convergent processes for the preparation of these taxane derivatives and their intermediates. | 12-10-2009 |
| 20120095237 | Process for the Preparation of 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylates - The present invention discloses a process for obtaining 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate (formula I) by the reaction of 4,4-dimethyl-2-propyl-4,6-dihydrofuro[3,4-d]imidazole (formula II), or its hydrolysis product, or its ring-opening product, with alcohol under appropriate catalytic conditions. Furthermore, the present invention also provides a process for obtaining high purity 4,4-dimethyl-2-propyl-4,6-dihydrofuro[3,4-d]imidazole (formula II), therefore purified compound of formula I can be produced. Producing of olmesartan medoxomil at high purity is assured by said processes. R in formula I is selected from C | 04-19-2012 |
| 20130338372 | Substituted Imidazoline Compounds - The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-κB. | 12-19-2013 |
| 20080207916 | Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives - The invention relates to radioactively labeled derivatives of (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid esters, uses, and methods for preparing these compounds. | 08-28-2008 |
| 20090156830 | Substituted Imidazoline Compounds - The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-κB. | 06-18-2009 |
| 20090306400 | CONVERGENT PROCESS FOR THE SYNTHESIS OF TAXANE DERIVATIVES. - The present invention is broadly directed to novel compounds useful for the synthesis of biologically active compounds, including taxane derivatives, and convergent processes for the preparation of these taxane derivatives and their intermediates. | 12-10-2009 |
| 20120095237 | Process for the Preparation of 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylates - The present invention discloses a process for obtaining 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate (formula I) by the reaction of 4,4-dimethyl-2-propyl-4,6-dihydrofuro[3,4-d]imidazole (formula II), or its hydrolysis product, or its ring-opening product, with alcohol under appropriate catalytic conditions. Furthermore, the present invention also provides a process for obtaining high purity 4,4-dimethyl-2-propyl-4,6-dihydrofuro[3,4-d]imidazole (formula II), therefore purified compound of formula I can be produced. Producing of olmesartan medoxomil at high purity is assured by said processes. R in formula I is selected from C | 04-19-2012 |
| 20130338372 | Substituted Imidazoline Compounds - The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-κB. | 12-19-2013 |
